Last reviewed · How we verify
Polydeoxyribonucleotide Injection
Polydeoxyribonucleotide (PDRN) is a naturally occurring polynucleotide that promotes tissue repair and regeneration by stimulating cellular metabolism and growth factor production.
Polydeoxyribonucleotide (PDRN) is a naturally occurring polynucleotide that promotes tissue repair and regeneration by stimulating cellular metabolism and growth factor production. Used for Wound healing and tissue repair, Chronic ulcers and dermatological lesions, Post-surgical wound management.
At a glance
| Generic name | Polydeoxyribonucleotide Injection |
|---|---|
| Sponsor | Chuncheon Sacred Heart Hospital |
| Drug class | Biogenic nucleotide/tissue repair agent |
| Target | Adenosine receptors (A2A) |
| Modality | Small molecule |
| Therapeutic area | Dermatology, Wound Healing, Regenerative Medicine |
| Phase | FDA-approved |
Mechanism of action
PDRN acts as a biogenic stimulant that enhances adenosine receptor signaling, particularly through A2A receptors, which increases cellular energy production and promotes angiogenesis. It stimulates fibroblast proliferation and collagen synthesis, facilitating wound healing and tissue regeneration. The mechanism involves activation of endogenous repair pathways and reduction of inflammatory responses.
Approved indications
- Wound healing and tissue repair
- Chronic ulcers and dermatological lesions
- Post-surgical wound management
Common side effects
- Local injection site reactions
- Mild erythema or edema
- Transient discomfort at injection site
Key clinical trials
- Comparative Study for Facial Scar Remodeling Using Fractional Carbon Dioxide Laser Combined With PDRN Versus Fractional CO₂ Laser (PHASE2)
- Regenarative Treatment of Periocular Wrinkles With PDRN (NA)
- Polydeoxyribonucleotide for Elbow Lateral Epicondylitis (NA)
- Effect of PDRN in Post-operative Scars (PHASE4)
- Effects and Safety of Epidural PDRN vs. Placebo (PHASE4)
- Bundang Rehabilitative Impact Study of the Elbow Epicondylitis (PHASE4)
- Polydeoxyribonucleotide -Placentex Mastelli(Pdrn) for the Treatment of Diabetic Ulcers (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Polydeoxyribonucleotide Injection CI brief — competitive landscape report
- Polydeoxyribonucleotide Injection updates RSS · CI watch RSS
- Chuncheon Sacred Heart Hospital portfolio CI